Integrated Carcinogenic Factor Evaluation & IARC Classification Mapping Service
Creative Biolabs' integrated carcinogenic factor evaluation (ICFE) service is purpose-built to navigate this complex evidence synthesis, delivering international agency for research on cancer (IARC)-compliant classifications (Group 1, 2A, 2B, 3) with unparalleled scientific rigor. We provide definitive evidence that translates directly into regulatory advantage, whether you need to confirm a low-risk profile for a novel drug candidate, resolve the ambiguity of an IARC Group 2B classification, or scientifically defend a read-across submission. By leveraging 20 years of expertise, Creative Biolabs ensures every assessment meets global compliance standards.
Background What We Can Offer Workflow Why Choose Us FAQs Customer Review Related Services Contact Us
Introduction of ICFE Service
The complexity of cancer hazard assessment—especially the challenging IARC Group 2B category—necessitates a shift from relying solely on resource-intensive animal bioassays to integrated, predictive systems. The Creative Biolabs ICFE service addresses this by fusing regulatory strategy with validated scientific new alternative methods (NAMs). We apply the IARC's key characteristics of carcinogens (KCCs) within the structured adverse outcome pathway (AOP) framework, using consensus quantitative structure-activity relationship (QSAR), high-throughput screening (HTS), and toxicogenomics to build a scientifically robust, regulator-accepted case for your compound's classification. This approach ensures maximal risk mitigation and accelerated compliance.
Key Deliverables and Solutions You Can Expect
Definitive IARC Classification
A clear, scientifically defensible final classification (Group 1, 2A, 2B, 3) aligned with the most current IARC preamble. This minimizes regulatory pushback and provides a firm basis for product safety statements.
Mode of Action (MOA) Clarity
A structured AOP narrative that verifies the human relevance of potential carcinogenic effects. This is the cornerstone for justifying non-relevance in human risk assessment.
Reduced Testing Burden
Strategic justification using consensus QSAR and read across to eliminate or minimize the requirement for expensive and time-consuming long-term animal bioassays, delivering high cost and time savings.
Predictive Lead Intelligence
Early-stage identification of specific molecular features (scaffolds, substructures) driving hazard, enabling targeted lead optimization and safer compound design before committing to costly development stages.
Ready to scope your project and timeline? Contact Creative Biolabs today to discuss your compound's specific needs with our expert team.
Workflow: From Compound Structure to Regulatory Certainty
The ICFE workflow is a comprehensive, multi-stage process designed to generate high-confidence mechanistic and predictive data suitable for regulatory submission. Each step is optimized to maximize data quality and regulatory compliance, guided by Creative Biolabs' expert toxicologists.
Why Choose Us?
Our commitment to integrating validated scientific methods with regulatory strategic thinking sets Creative Biolabs apart. We don't just predict; we provide the defensible, transparent, and interpretable evidence required for global market access and regulatory confidence.
20+ Years of Specialization
Unmatched experience in complex biological and toxicological evaluations, providing authoritative results that stand up to regulatory scrutiny.
MOA/AOP Framework Expertise
We don't just list data; we structure it into a compelling, regulator-accepted causal narrative, ensuring the human relevance of the hazard.
Strategic Read-Across Expertise
Fills critical data gaps for novel or data-poor compounds, drastically reducing the need for costly and time-consuming long-term animal testing.
State-of-the-Art NAMs Integration
Combines toxicogenomics, HTS, and consensus QSAR/ML to create a predictive data stream, providing regulatory-ready evidence and eliminating the dependency on traditional animal studies.
To build a complete, integrated toxicological profile, explore our full suite of NAMs services. Click here to learn more about our complementary offerings.
FAQs
How do your consensus QSAR models compare to common commercial predictive software?
Our consensus QSAR models are integrated into a larger NAMs framework, leveraging multiple distinct machine learning and deep learning algorithms against diverse feature sets. This ensemble approach significantly improves predictive reliability and generalization ability over single-model systems.
Can the ICFE Service completely replace long-term animal carcinogenicity studies?
The ICFE service is a strategic tool that reduces animal studies by providing compelling evidence for low-hazard classification, justifying read-across, and resolving IARC ambiguities early.
What specific data is generated to support the KCCs?
We use a multi-omics approach. KCCs 1/4 are addressed by QSAR/HTS, while KCCs 3, 5, and 8 are supported by toxicogenomics (transcriptomics) to detect pathway perturbations.
Customer Review
-
Highly Accurate Genotoxicity Prediction
The Consensus QSAR component rapidly flagged and helped resolve genotoxicity alerts (KCC 1) for 15 scaffolds, giving us high confidence before initiating costly in vitro Ames testing. Their predictive accuracy is unmatched by standard commercial software. – Aw*Fs
-
Resolution of IARC Group 2B Ambiguity
Their MOA/AOP framework provided the irrefutable evidence needed to defend our compound's non-relevance to human carcinogenicity, successfully differentiating it from other IARC Group 2B agents and providing crucial clarity for our preclinical path. – Sa*Pr
Related Services
Creative Biolabs offers several complementary services that can further enhance your hazard and safety assessment strategy, working in conjunction with the ICFE service to provide a complete toxicological profile.
Genotoxicity Assessment Services
Creative Biolabs provides comprehensive genotoxicity assessment services to evaluate a compound's potential to damage genetic material, providing critical data for drug safety and regulatory submissions.
Learn More →
Therapeutic Antibody & Protein Development Services
Creative Biolabs offers integrated therapeutic antibody and protein discovery services, leveraging senior scientific expertise and best-in-class equipment, guiding clients from target selection to regulatory support.
Learn More →
How to Contact Creative Biolabs
The cost of uncertainty in carcinogenicity assessment is immeasurable. Creative Biolabs' ICFE and IARC classification mapping service transforms regulatory complexity into a competitive advantage by delivering high-confidence, scientifically defensible hazard conclusions through validated NAMs.
Contact our expert team today to schedule a confidential consultation and map your compound's definitive path to regulatory success.
For Research Use Only | Not For Clinical Use
Download our brochure